Silexion Therapeutics Announces First Patient Dosed Phase 2/3 Clinical Trial Evaluating Lead Candidate, SIL204, In Patients With Locally Advanced Pancreatic Cancer
Global Phase 2/3 trial evaluates SIL204 in combination with standard chemotherapy in patients with locally advanced pancreatic cancerIntegrated regimen combines direct EUS-guided intratumoral delivery to penetrate tumor
Silexion started testing a new pancreatic cancer medicine on real patients. Watch to see if the treatment works better than regular medicines.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.